SecBot

SecBot
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001750284

OLMA

Olema Pharmaceuticals, Inc.
$8.23 ▼ -0.54%
Prev close $8.27
Market cap$756.0M
ConsensusStrong Buy
12-mo target$36.50 (+343.8%)
▲ Bullish
Analyst conviction 9/10
30 New Institutional Positions20 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on OLMA right now — valuation, ownership and activity at a glance.
Market Cap
$756.0M
Cap Size
Small Cap
Analyst Consensus
Strong Buy (89%)
Inst. Holders
50 funds
Inst. Value
$716.9M
Inst. Activity
30 buys / 20 sells
Insider Activity
$0.00 buy / $1.2M sell
Insider Net $
-$1.2M
SEC Reports
8
Press Releases
5
Price chart 30d -23.3%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 activist
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Onco
Sep 1, 2026 Insider
O'Byrne Jason was granted 650,000 shares
CHIEF FINANCIAL OFFICER
Aug 10, 2026 SEC
Olema Pharmaceuticals reported a Q2 2026 net loss of $63.2M, wider than the $43.8M loss in Q2 2025, driven by increased
8-K — Impact 5/10
Aug 10, 2026 SEC
Olema Oncology's Q2 2026 net loss widened to $63.2M (vs $43.8M a year ago) on higher R&D and G&A spending, but cash of $
PRESS-RELEASE — Impact 4/10
Aug 9, 2026 SEC
Institutional cluster for OLMA shows net selling of ~$27.4M in Q2 2026, driven by Jennison Associates' full exit of a $2
INST-CLUSTER — Impact 6/10
Jul 24, 2026 Insider
Harmon Cyrus sold 12,500 shares
Director @ $11.71 ($146.4K)
Jul 23, 2026 Insider
Harmon Cyrus sold 12,500 shares
Director @ $11.58 ($144.7K)
Jun 30, 2026 Inst.
MORGAN STANLEY — ADD
1,832,269 shares ($22.9M)
Analyst ratings buy % -4.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Strong Buy 89% rate it Buy or better · 18 analysts
Strong Buy 6 33% Buy 10 56% Hold 2 11% Sell 0 0% Strong Sell 0 0%
Recent analyst actions
DateFirmActionRatingFirm rating
Sep 14, 2026StifelMAINTAINBuy 54%
Aug 13, 2026JP MorganMAINTAINOverweight 55%
Aug 11, 2026CitigroupMAINTAINBuy 55%
Aug 11, 2026HC Wainwright & Co.MAINTAINBuy 43%
May 13, 2026GuggenheimMAINTAINBuy 52%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 202661020089%
Aug 1, 202661020089%
Jul 1, 202661020089%
Jun 1, 202671020089%
May 1, 202671020089%
Apr 1, 202671020089%
Mar 1, 202671010094%
Feb 1, 202661010094%
Price targets
Where 10 covering analysts think OLMA trades over the next 12 months.
$36.50 +343.8% upside Strong Buy
Current$8.23 Low$16.00 Median$38.00 High$59.00 10 analysts
$16.00$59.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
8 SEC filing reports analyzed · 2 bullish, 1 bearish, 0 mixed, 5 neutral · avg impact 4.8/10.Plus 5 press releases.
NEUTRAL8-K5/10
Olema Pharmaceuticals reported a Q2 2026 net loss of $63.2M, wider than the $43.8M loss in Q2 2025,
Aug 10, 2026
NEUTRALPRESS-RELEASE4/10
Olema Oncology's Q2 2026 net loss widened to $63.2M (vs $43.8M a year ago) on higher R&D and G&A spe
Aug 10, 2026
BEARISHINST-CLUSTER6/10
Institutional cluster for OLMA shows net selling of ~$27.4M in Q2 2026, driven by Jennison Associate
Aug 9, 2026
BULLISH8-K6/10
Olema Pharmaceuticals announced a clinical trial collaboration and supply agreement with Bayer to ev
May 26, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
activist
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmace
Sep 30, 2026
short_volume
Short Volume: OLMA — 67.0% short (0.4M / 0.6M)
Short: 419,652 | Exempt: 0 | TRF Vol: 626,394 | Short Ratio: 67.0% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
short_volume
Short Volume: OLMA — 65.2% short (0.4M / 0.6M)
Short: 362,859 | Exempt: 0 | TRF Vol: 556,356 | Short Ratio: 65.2% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: OLMA — 56.2% short (0.5M / 0.8M)
Short: 465,023 | Exempt: 0 | TRF Vol: 827,283 | Short Ratio: 56.2% | Off-exchange volume (dark pool + OTC)
Sep 2, 2026
other
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmac
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$-0.63$-0.73–$-0.50-29.4%+1.7%1↑ 7↓$0.0B9
Next Q$-0.66$-0.73–$-0.52-31.2%+2.0%1↑ 7↓$0.0B9
Current FY$-2.38$-2.69–$-1.92-27.2%+1.8%1↑ 7↓$0.0B9
Next FY$-2.64$-3.09–$-2.04-10.9%+1.9%1↑ 7↓$0.0B9
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$-0.634—
7d ago$-0.631-0.003
30d ago$-0.645+0.011
60d ago$-0.579-0.055
90d ago$-0.579-0.055
Institutional ownership
Which big funds own OLMA (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $716.9M total value (57,292,490 shares) as of 2026-Q2. Top holders: FMR, Jupiter, BlackRock,. Net buying activity: 30 institutions added/increased vs 20 reduced.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
FMR LLC12,143,062$151.9M21.2%—
Jupiter Topco LLC7,094,413$88.8M12.4%—
BlackRock, Inc.6,714,691$84.0M11.7%—
STATE STREET CORP4,316,058$54.0M7.5%—
VANGUARD CAPITAL MANAGEMENT LLC3,341,217$41.8M5.8%—
FRANKLIN RESOURCES INC2,349,586$29.4M4.1%—
MORGAN STANLEY1,832,269$22.9M3.2%ADD +50.7%
GEODE CAPITAL MANAGEMENT, LLC1,819,029$22.8M3.2%—
VANGUARD PORTFOLIO MANAGEMENT LLC1,663,218$20.8M2.9%DOUBLED +180.5%
GOLDMAN SACHS GROUP INC1,567,979$19.6M2.7%ADD +50.0%
Recent position changes
FundActionPrevCurrentChangeValue
MORGAN STANLEYADD1,215,6901,832,269+50.7%$22.9M
VANGUARD PORTFOLIO MANAGEMENT LLCDOUBLED593,0311,663,218+180.5%$20.8M
GOLDMAN SACHS GROUP INCADD1,045,5891,567,979+50.0%$19.6M
DIMENSIONAL FUND ADVISORS LPADD1,082,4341,416,533+30.9%$17.7M
Point72 Asset Management, L.P.DOUBLED71,1071,070,949+1406.1%$13.4M
AMERIPRISE FINANCIAL INCDOUBLED57,362840,646+1365.5%$10.5M
Woodline Partners LPTRIM1,482,030751,030-49.3%$9.4M
Qube Research & Technologies LtdDOUBLED312,812663,319+112.1%$8.3M
CITADEL ADVISORS LLCTRIM905,332641,828-29.1%$8.0M
Hudson Bay Capital Management LPDOUBLED154,770566,400+266.0%$7.1M
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
17 insiders, 31 transactions. Net -$1.2M — $0.00 bought, $1.2M sold.
DateInsiderTitleTypeSharesPriceValue
Sep 1, 2026O'Byrne JasonCHIEF FINANCIAL OFFICERAWARD650,000——
Jul 24, 2026Harmon CyrusDirectorSELL12,500$11.71$146.4K
Jul 23, 2026Harmon CyrusDirectorSELL12,500$11.58$144.7K
Jun 18, 2026Graham G. WalmsleyDirectorAWARD29,500——
Jun 18, 2026RAPPAPORT ANDREWDirectorAWARD29,500——
Jun 18, 2026Raman PrakashDirectorAWARD29,500——
Jun 18, 2026Horning SandraDirectorAWARD29,500——
Jun 18, 2026Larson YiDirectorAWARD29,500——
Jun 18, 2026CLARK IAN TDirectorAWARD29,500——
Jun 18, 2026Hrustanovic GorjanDirectorAWARD29,500——
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for OLMA.
Shares short
16,068,469
Settlement Sep 15, 2026
Change vs prior
+2.6%
Semi-monthly cycle
Days to cover
15.9
At avg daily volume
Of shares outstanding
≈18.4%
Estimate — not % of float
All OLMA filing & press-release reports (13)